Cue Biopharma Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
CUE$20.14+7.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| September 30,2024 | December 31,2023 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $32,420 | $48,514 |
| Accounts receivable | 3,152 | 1,698 |
| Prepaid expenses and other current assets | 1,684 | 1,242 |
| Total current assets | 37,256 | 51,454 |
| Property and equipment, net | 570 | 795 |
| Operating lease right-of-use assets | 4,034 | 6,323 |
| Deposits | 2,690 | 2,690 |
| Restricted cash | 152 | 151 |
| Other long-term assets | 108 | 117 |
| Total assets | $44,810 | $61,530 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $6,474 | $3,501 |
| Accrued expenses | 3,199 | 4,137 |
| Research and development contract liability, current portion | 259 | 2,112 |
| Operating lease liabilities, current | 2,895 | 3,368 |
| Current portion of long-term debt, net | 3,963 | 3,963 |
| Total current liabilities | 16,790 | 17,081 |
| Operating lease liabilities, non-current | 1,326 | 3,162 |
| Long-term debt, net | 1,328 | 4,202 |
| Total liabilities | $19,444 | $24,445 |
| Commitments and contingencies (Note 11) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized and 0 shares issued and outstanding at September 30, 2024 and December 31, 2023 | — | — |
| Common stock, $0.001 par value; 100,000,000 shares authorized; 60,207,717 and 47,215,116 shares issued and outstanding, at September 30, 2024 and December 31, 2023, respectively | 60 | 47 |
| Additional paid in capital | 357,674 | 338,228 |
| Accumulated deficit | (332,368) | (301,190) |
| Total stockholders’ equity | 25,366 | 37,085 |
| Total liabilities and stockholders’ equity | $44,810 | $61,530 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.